1L Pancreatic ductal adenocarcinoma (PDAC)
RCUSArcus BiosciencesCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Quemliclustat + Gemcitabine/Nab-Paclitaxel v.s. Gemcitabine/Nab-Paclitaxel in 1L Pancreatic ductal adenocarcinoma (PDAC). The expected timing is based on the latest available company guidance and may change.
PRISM-1 trial. Q4 2024- Trial initiated. 2/25- Partnered w/ Taiho to dose 1st participant in Japan. 2/25/25- Trial ongoing. 7/10/25- FDA orphan drug designation. Full enrollment by YE 2025. 10/28/25:- Ph3 PRISM-1 fully enrolled within 12 months of initiation; readout timing not disclosed. 12/12/25:- PRISM-1 enrollment completed earlier 2025; Phase 3 pancreatic cancer results expected in 2027. 02/25/26:- PRISM-1 enrollment completed September 2025; Phase 3 metastatic PDAC results expected in H1 2027. 05/05/26:- PRISM-1 enrollment completion in September 2025 and H1 2027 results timing reiterated. 08/05/26:- PRISM-1 enrollment and H1 2027 results timing reiterated.
Verification
Confirm timing and program details against the company announcement or filing.